Skip to content

Your Weekly Digest | Issue 51

Valur Thrainsson
2 min read

Good morning,

Here below you find the most read articles on CompetitionFeed over the last week.


Bayer, Monsanto deal on track for U.S. approval by end of May: source

WASHINGTON (Reuters) - German drug and crop chemical maker Bayer AG’s bid to buy seed and chemical company Monsanto Co is on track to win U.S. antitrust approval by the end of May, unless there is a last-minute complication, a source familiar with the matter said on Thursday. Read More.


Asda Sainsbury's merger talks 'sign of changing retail world'

Could the big four become the big three? It's a question many had been asking given how the grocery landscape has been changing. Read More.


CMA finds competition concerns in construction merger

The CMA has identified competition concerns following an investigation into the proposed purchase of concrete plants by a building materials company. Read More.

The Conversation

How courts and costs are undermining ASIC and the ACCC’s efforts to police misbehaving banks and businesses

The Australian Securities and Investments Commission (ASIC) has come under heavy fire for taking the lighter option of securing undertakings from businesses in breach of the law, rather than tougher penalties. Read More.

The MEO ruling: applying Intel to discriminatory pricing

The MEO ruling: applying Intel to discriminatory pricing

On 19 April 2018, the Court of Justice (CJEU) issued an important ruling in the MEO case on the interpretation of Article 102(c) TFEU.[1] Article 102 prohibits, as incompatible with the EU’s internal market, any abuse by one or more undertakings of a dominant position in so far as it may affect trade between Member States. Read More.

Truth on the Market

Net Neutrality Paranoia

The paranoid style is endemic across the political spectrum, for sure, but lately, in the policy realm haunted by the shambling zombie known as “net neutrality,” the pro-Title II set are taking the rhetoric up a notch. Read More.

Review of Industrial Organization

The Impact of the Entry of Biosimilars: Evidence from Europe

Fiona M. Scott Morton, Ariel Dora Stern, Scott Stern
Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry, however only a few biosimilars have been approved in the US since 2015, thereby largely preserving biologics from competition. Read More.

UC Hastings Research Paper No. 269

Empirical Evidence of Drug Companies Using Citizen Petitions to Hold Off Competition

Robin Feldman, John Gray, Giora Ashkenazi
The FDA’s citizen petition process was created in the 1970s as part of an effort to fashion more participatory regimes, in which ordinary citizens could access the administrative process. Read More.

Journal of Competition Law & Economics


Thomas W Hazlett, Sarah Oh, Brent Skorup
Vertical restrictions have theoretically ambiguous efficiency effects. Marketplace evidence is, therefore, required to reveal the presence of anticompetitive foreclosure. Read More.

Visit CompetitionFeed and read more.

Best wishes, CompetitionFeed Team

About CompetitionFeed
By aggregating material from over 300 sources and using human and artificial intelligence to pick out the most important articles, CompetitionFeed provides an effective way to monitor all this information. That would be impossible for any single person.

Events and Jobs
Looking for a job or an interesting event to attend? Visit